What diseases is Fenelidone mainly used to treat?

Finerenone is a new, non-steroidal selective aldosterone receptor antagonist (MRA), mainly used to treat chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The drug's main mechanism of action is to reduce inflammation and fibrosis in the kidneys and cardiovascular system by blocking aldosterone receptors, thereby reducing the risk of worsening kidney function and cardiovascular complications.

In patients with chronic kidney disease and diabetes, hyperglycemia can cause chronic inflammation and oxidative stress, leading to renal tubulointerstitial damage, which in turn aggravates proteinuria and decreased renal function. Aldosterone is one of the key hormones in theRAAS (renin-angiotensin-aldosterone system), which promotes sodium retention and vasoconstriction, further exacerbating kidney damage. By highly selectively antagonizing aldosterone receptors, fenelidone reduces the inflammatory response and the incidence of glomerulosclerosis and interstitial fibrosis, thereby delaying the progression of kidney disease and reducing the risk of cardiovascular events, such as heart failure hospitalization and cardiovascular death.

Large clinical studies Both FIDELIO-DKD and FIGARO-DKD have confirmed that fenelinone has significant efficacy in reducing proteinuria, slowing down the decline of eGFR, reducing the risk of renal failure and adverse cardiovascular events. In addition, research also shows that the drug may also have potential benefits for chronic kidney disease in non-diabetic patients, but the current main indication is still limited to patients with T2D and CKD. Compared with traditional steroidal aldosterone antagonists such as spironolactone and eplerenone, fenelinone has higher selectivity and reduces side effects such as water and sodium retention and hyperkalemia, making it more suitable for the long-term treatment of patients with chronic kidney disease.

In addition, fenelidone has also shown some protective effects in some studies of hypertension-related kidney disease, but it has not been approved for the treatment of other types of kidney disease.

Reference materials:https://www.kerendia.com/